ZA200506411B - Peptide inhibitors of toxins derived from LL-37 - Google Patents

Peptide inhibitors of toxins derived from LL-37 Download PDF

Info

Publication number: ZA200506411B
Authority: ZA; South Africa
Prior art keywords: compound; acid sequence; terminal part; amino acids; compounds
Prior art date: 2003-01-28

Application number

ZA200506411A

Other languages

English (en)

Inventor

Johannes J Grote

Jan W Drijfhout

Original Assignee

Academisch Ziekenhuis Leiden

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-28

Filing date

2005-08-11

Publication date

2006-04-26

2005-08-11 Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden

2006-04-26 Publication of ZA200506411B publication Critical patent/ZA200506411B/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 75
POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 title description 22
239000003053 toxin Substances 0.000 title description 19
231100000765 toxin Toxicity 0.000 title description 19
108700012359 toxins Proteins 0.000 title description 19
239000003112 inhibitor Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 100
150000001413 amino acids Chemical class 0.000 claims abstract description 49
239000002158 endotoxin Substances 0.000 claims abstract description 34
229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 28
210000004899 c-terminal region Anatomy 0.000 claims abstract description 23
239000000688 bacterial toxin Substances 0.000 claims abstract description 19
239000002253 acid Substances 0.000 claims abstract description 18
230000001580 bacterial effect Effects 0.000 claims abstract description 10
239000002636 mycotoxin Substances 0.000 claims abstract description 8
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
231100000699 Bacterial toxin Toxicity 0.000 claims description 17
238000000034 method Methods 0.000 claims description 17
210000004027 cell Anatomy 0.000 claims description 14
239000013598 vector Substances 0.000 claims description 13
208000005923 otitis media with effusion Diseases 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
150000007523 nucleic acids Chemical group 0.000 claims description 10
108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
230000001154 acute effect Effects 0.000 claims description 8
230000002538 fungal effect Effects 0.000 claims description 8
230000001225 therapeutic effect Effects 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
238000002560 therapeutic procedure Methods 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 5
150000002632 lipids Chemical class 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
239000013603 viral vector Substances 0.000 claims description 5
208000035143 Bacterial infection Diseases 0.000 claims description 4
206010017533 Fungal infection Diseases 0.000 claims description 4
208000031888 Mycoses Diseases 0.000 claims description 4
208000022362 bacterial infectious disease Diseases 0.000 claims description 4
230000014509 gene expression Effects 0.000 claims description 4
238000003745 diagnosis Methods 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
230000008685 targeting Effects 0.000 claims description 3
206010001076 Acute sinusitis Diseases 0.000 claims description 2
206010009137 Chronic sinusitis Diseases 0.000 claims description 2
208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
238000003973 irrigation Methods 0.000 claims description 2
230000002262 irrigation Effects 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
210000002345 respiratory system Anatomy 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
210000001519 tissue Anatomy 0.000 claims description 2
239000000443 aerosol Substances 0.000 claims 2
238000001476 gene delivery Methods 0.000 claims 2
239000007788 liquid Substances 0.000 claims 2
108700005078 Synthetic Genes Proteins 0.000 claims 1
108700005077 Viral Genes Proteins 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
150000003862 amino acid derivatives Chemical class 0.000 claims 1
208000024035 chronic otitis media Diseases 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
229940124447 delivery agent Drugs 0.000 claims 1
239000000032 diagnostic agent Substances 0.000 claims 1
229940039227 diagnostic agent Drugs 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
239000003221 ear drop Substances 0.000 claims 1
229940047652 ear drops Drugs 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
238000007918 intramuscular administration Methods 0.000 claims 1
230000003232 mucoadhesive effect Effects 0.000 claims 1
210000004877 mucosa Anatomy 0.000 claims 1
229940100662 nasal drops Drugs 0.000 claims 1
238000002663 nebulization Methods 0.000 claims 1
239000000843 powder Substances 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
239000003981 vehicle Substances 0.000 claims 1
230000003612 virological effect Effects 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 description 43
229940024606 amino acid Drugs 0.000 description 28
235000001014 amino acid Nutrition 0.000 description 27
230000000694 effects Effects 0.000 description 16
208000015181 infectious disease Diseases 0.000 description 12
239000000126 substance Substances 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
241000894006 Bacteria Species 0.000 description 9
102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
229940088710 antibiotic agent Drugs 0.000 description 7
230000003115 biocidal effect Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
210000000959 ear middle Anatomy 0.000 description 7
101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 6
238000013459 approach Methods 0.000 description 5
108091005601 modified peptides Proteins 0.000 description 5
238000006386 neutralization reaction Methods 0.000 description 5
230000003472 neutralizing effect Effects 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 4
231100000757 Microbial toxin Toxicity 0.000 description 4
208000005141 Otitis Diseases 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
244000052616 bacterial pathogen Species 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
208000019258 ear infection Diseases 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
-1 peptide LL-37 Chemical compound 0.000 description 4
239000000816 peptidomimetic Substances 0.000 description 4
101710140438 Cathelicidin antimicrobial peptide Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108010043958 Peptoids Proteins 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
235000011054 acetic acid Nutrition 0.000 description 3
230000021736 acetylation Effects 0.000 description 3
238000006640 acetylation reaction Methods 0.000 description 3
230000009435 amidation Effects 0.000 description 3
238000007112 amidation reaction Methods 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
102000014509 cathelicidin Human genes 0.000 description 3
108060001132 cathelicidin Proteins 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
230000006870 function Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
150000008574 D-amino acids Chemical class 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
206010034133 Pathogen resistance Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
125000000837 carbohydrate group Chemical group 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000036039 immunity Effects 0.000 description 2
208000022760 infectious otitis media Diseases 0.000 description 2
230000001524 infective effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000000420 mucociliary effect Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
101710182546 Antimicrobial protein CAP18 Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000018389 Exopeptidases Human genes 0.000 description 1
108010091443 Exopeptidases Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000589774 Pseudomonas sp. Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
108010065183 antilipopolysaccharide antibodies Proteins 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
108010007004 cathelin Proteins 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000000562 conjugate Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000007108 local immune response Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920002851 polycationic polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000016412 positive regulation of cytokine production Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008261 resistance mechanism Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical group S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
150000003512 tertiary amines Chemical group 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
229960001262 tramazoline Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
239000000277 virosome Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Pulmonology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200506411A 2003-01-28 2005-08-11 Peptide inhibitors of toxins derived from LL-37 ZA200506411B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03075274		2003-01-28

Publications (1)

Publication Number	Publication Date
ZA200506411B true ZA200506411B (en)	2006-04-26

Family

ID=32798944

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200506411A ZA200506411B (en)	2003-01-28	2005-08-11	Peptide inhibitors of toxins derived from LL-37

Country Status (19)

Country	Link
US (1)	US7807617B2 (ru)
EP (1)	EP1587830B1 (ru)
JP (1)	JP4471968B2 (ru)
KR (1)	KR100856819B1 (ru)
CN (1)	CN1798764B (ru)
AT (1)	ATE435870T1 (ru)
AU (1)	AU2004207118B2 (ru)
BR (1)	BRPI0407022A (ru)
CA (1)	CA2514584C (ru)
CR (1)	CR7926A (ru)
DE (1)	DE602004021901D1 (ru)
DK (1)	DK1587830T3 (ru)
ES (1)	ES2328571T3 (ru)
MX (1)	MXPA05008080A (ru)
NZ (1)	NZ541657A (ru)
PT (1)	PT1587830E (ru)
RU (1)	RU2346950C2 (ru)
WO (1)	WO2004067563A1 (ru)
ZA (1)	ZA200506411B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1621205A1 (en) *	2004-07-28	2006-02-01	OctoPlus Technologies B.V.	Antimicrobial peptides derived from CAP18
US7465784B2 (en) *	2006-10-26	2008-12-16	Board Of Regents Of The University Of Nebraska	Antimicrobial peptides and methods of identifying the same
BRPI0814363A2 (pt)	2007-07-25	2015-01-27	Biolex Therapeutics Inc	Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
WO2011103666A1 (en) *	2010-02-25	2011-09-01	University Of Manitoba	Modulation of cytokine-induced chronic inflammatory responses
US8680697B2 (en)	2011-11-21	2014-03-25	Jasem M. J. Alqanee	Roadway bump electricity generation system
US10723764B2 (en)	2011-11-21	2020-07-28	Board Of Regents Of The University Of Nebraska	Anti-microbial peptides and methods of use thereof
IL314360B2 (en) *	2012-09-17	2025-09-01	F Hoffmann La Roche Ltd	Method for the synthesis of thyroid hormone analogs and their polymorphs
CN107074941A (zh)	2014-11-10	2017-08-18	豪夫迈·罗氏有限公司	双特异性抗体和用于眼科学的方法
RU2584089C1 (ru) *	2015-06-15	2016-05-20	Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Медицинский Университет Имени В.И. Разумовского" Министерства Здравоохранения Российской Федерации	Способ снижения летального эффекта бактериального липополисахарида in vitro
CN105859867A (zh) *	2016-05-30	2016-08-17	黄石市中心医院	一种人源抗菌肽ll-37突变体及其应用
CN108892719B (zh) *	2018-07-09	2021-07-30	珠海中科先进技术研究院有限公司	一种新型人源抗菌肽ll-37衍生物及其应用
CN113116811A (zh) *	2020-01-14	2021-07-16	中国科学院上海药物研究所	可注射长效镇痛药物组合物及其制备方法和用途
EP4091612B1 (en) *	2020-01-14	2025-11-12	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
WO2024223883A1 (en)	2023-04-26	2024-10-31	Karl-Franzens-Universität Graz	Peptides for cancer therapy
WO2024223887A1 (en)	2023-04-26	2024-10-31	Karl-Franzens-Universität Graz	Peptides for antimicrobial therapy
CN118754950B (zh) *	2024-06-07	2025-03-07	扬州大学	一种抗菌衍生肽及其组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6103888A (en) *	1992-07-17	2000-08-15	Panorama Research, Inc.	Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
US5681824A (en) *	1995-06-05	1997-10-28	Eisai Co., Ltd.	Substituted liposaccharides useful in the treatment and prevention of endotoxemia
JP4037525B2 (ja) *	1998-03-25	2008-01-23	生化学工業株式会社	新規抗菌性ペプチド

2004
- 2004-01-27 BR BR0407022-4A patent/BRPI0407022A/pt not_active IP Right Cessation
- 2004-01-27 KR KR1020057013964A patent/KR100856819B1/ko not_active Expired - Fee Related
- 2004-01-27 DK DK04705556T patent/DK1587830T3/da active
- 2004-01-27 AU AU2004207118A patent/AU2004207118B2/en not_active Ceased
- 2004-01-27 CA CA2514584A patent/CA2514584C/en not_active Expired - Fee Related
- 2004-01-27 JP JP2006502728A patent/JP4471968B2/ja not_active Expired - Fee Related
- 2004-01-27 US US10/543,521 patent/US7807617B2/en not_active Expired - Fee Related
- 2004-01-27 CN CN2004800085269A patent/CN1798764B/zh not_active Expired - Fee Related
- 2004-01-27 WO PCT/NL2004/000060 patent/WO2004067563A1/en not_active Ceased
- 2004-01-27 MX MXPA05008080A patent/MXPA05008080A/es not_active Application Discontinuation
- 2004-01-27 EP EP04705556A patent/EP1587830B1/en not_active Expired - Lifetime
- 2004-01-27 RU RU2005127076/04A patent/RU2346950C2/ru not_active IP Right Cessation
- 2004-01-27 ES ES04705556T patent/ES2328571T3/es not_active Expired - Lifetime
- 2004-01-27 AT AT04705556T patent/ATE435870T1/de active
- 2004-01-27 PT PT04705556T patent/PT1587830E/pt unknown
- 2004-01-27 NZ NZ541657A patent/NZ541657A/en not_active IP Right Cessation
- 2004-01-27 DE DE602004021901T patent/DE602004021901D1/de not_active Expired - Lifetime
2005
- 2005-07-28 CR CR7926A patent/CR7926A/es not_active Application Discontinuation
- 2005-08-11 ZA ZA200506411A patent/ZA200506411B/en unknown

Also Published As

Publication number	Publication date
KR20060012261A (ko)	2006-02-07
DK1587830T3 (da)	2009-10-26
CN1798764A (zh)	2006-07-05
DE602004021901D1 (de)	2009-08-20
BRPI0407022A (pt)	2006-01-10
RU2005127076A (ru)	2006-01-20
HK1088613A1 (zh)	2006-11-10
PT1587830E (pt)	2009-09-23
NZ541657A (en)	2009-01-31
WO2004067563A8 (en)	2004-12-02
CA2514584C (en)	2012-05-29
CR7926A (es)	2006-02-07
US20060223755A1 (en)	2006-10-05
KR100856819B1 (ko)	2008-09-05
JP2007528696A (ja)	2007-10-18
ATE435870T1 (de)	2009-07-15
EP1587830B1 (en)	2009-07-08
AU2004207118A1 (en)	2004-08-12
MXPA05008080A (es)	2006-02-08
US7807617B2 (en)	2010-10-05
EP1587830A1 (en)	2005-10-26
AU2004207118B2 (en)	2009-12-17
CA2514584A1 (en)	2004-08-12
CN1798764B (zh)	2010-05-12
RU2346950C2 (ru)	2009-02-20
ES2328571T3 (es)	2009-11-16
JP4471968B2 (ja)	2010-06-02
WO2004067563A1 (en)	2004-08-12

Publication	Publication Date	Title
CA2372821C (en)	2014-07-08	Antimicrobial theta defensins and methods of using same
JP5322108B2 (ja)	2013-10-23	抗菌ペプチド
ZA200506411B (en)	2006-04-26	Peptide inhibitors of toxins derived from LL-37
US5786324A (en)	1998-07-28	Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
JP2000513209A (ja)	2000-10-10	抗微生物ペプチドと使用方法
JP2002544759A (ja)	2002-12-24	カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法
JPWO1996006181A1 (ja)	1996-12-24	蛋白質の修飾方法
KR20160018549A (ko)	2016-02-17	항균 펩티드
CN106164087A (zh)	2016-11-23	抗微生物多肽及其用途
AU2005267651B2 (en)	2010-05-27	Antimicrobial peptides derived from CAP18
US6696274B2 (en)	2004-02-24	Ligand for enhancing oral and CNS delivery of biological agents
US20030219854A1 (en)	2003-11-27	Methods for producing modified anti-infective peptides
CA2451310C (en)	2014-02-25	Antimicrobial peptides
HRP20040127A2 (en)	2004-06-30	Peptidic compounds selectively binding top p-selection
CA2408387A1 (en)	2001-11-29	A ligand for enhancing oral and cns delivery of biological agents
HK1088613B (en)	2010-12-17	Peptide inhibitors of toxins derived from ll-37
HK1102693A (en)	2007-11-30	Antimicrobial peptides derived from cap18
WO2013023166A2 (en)	2013-02-14	Hapivirins and diprovirins
JPH03178991A (ja)	1991-08-02	ペプチド性抗生物質